nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—CYP3A4—Pilocarpine—glaucoma	0.0645	0.166	CbGbCtD
Canagliflozin—ABCB1—Timolol—glaucoma	0.0619	0.159	CbGbCtD
Canagliflozin—ABCB1—Clonidine—glaucoma	0.0526	0.135	CbGbCtD
Canagliflozin—CYP3A4—Brinzolamide—glaucoma	0.0506	0.13	CbGbCtD
Canagliflozin—CYP3A4—Dorzolamide—glaucoma	0.0489	0.126	CbGbCtD
Canagliflozin—CYP3A4—Methazolamide—glaucoma	0.0436	0.112	CbGbCtD
Canagliflozin—CYP3A4—Acetazolamide—glaucoma	0.0348	0.0897	CbGbCtD
Canagliflozin—CYP3A4—Clonidine—glaucoma	0.0315	0.0811	CbGbCtD
Canagliflozin—Hypersensitivity—Metipranolol—glaucoma	0.0014	0.00299	CcSEcCtD
Canagliflozin—Urinary tract disorder—Travoprost—glaucoma	0.0014	0.00299	CcSEcCtD
Canagliflozin—Urethral disorder—Travoprost—glaucoma	0.00138	0.00297	CcSEcCtD
Canagliflozin—Hypoglycaemia—Betaxolol—glaucoma	0.00138	0.00296	CcSEcCtD
Canagliflozin—Urinary tract disorder—Brinzolamide—glaucoma	0.00138	0.00295	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methazolamide—glaucoma	0.00137	0.00294	CcSEcCtD
Canagliflozin—Fatigue—Methazolamide—glaucoma	0.00137	0.00294	CcSEcCtD
Canagliflozin—Urethral disorder—Brinzolamide—glaucoma	0.00137	0.00293	CcSEcCtD
Canagliflozin—Asthenia—Metipranolol—glaucoma	0.00136	0.00291	CcSEcCtD
Canagliflozin—Syncope—Apraclonidine—glaucoma	0.00135	0.0029	CcSEcCtD
Canagliflozin—Angiopathy—Brimonidine—glaucoma	0.00135	0.00289	CcSEcCtD
Canagliflozin—Abdominal pain—Carbachol—glaucoma	0.00133	0.00285	CcSEcCtD
Canagliflozin—Urticaria—Levobunolol—glaucoma	0.00132	0.00282	CcSEcCtD
Canagliflozin—Erythema—Brimonidine—glaucoma	0.00129	0.00277	CcSEcCtD
Canagliflozin—Hypersensitivity—Carteolol—glaucoma	0.00129	0.00277	CcSEcCtD
Canagliflozin—Angiopathy—Travoprost—glaucoma	0.00128	0.00275	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.00127	0.00273	CcSEcCtD
Canagliflozin—Angiopathy—Brinzolamide—glaucoma	0.00127	0.00271	CcSEcCtD
Canagliflozin—Urticaria—Methazolamide—glaucoma	0.00126	0.00271	CcSEcCtD
Canagliflozin—Asthenia—Carteolol—glaucoma	0.00126	0.0027	CcSEcCtD
Canagliflozin—Dry mouth—Apraclonidine—glaucoma	0.00125	0.00269	CcSEcCtD
Canagliflozin—Dizziness—Metipranolol—glaucoma	0.00125	0.00269	CcSEcCtD
Canagliflozin—Asthenia—Diclofenamide—glaucoma	0.00124	0.00265	CcSEcCtD
Canagliflozin—Pollakiuria—Clonidine—glaucoma	0.00124	0.00265	CcSEcCtD
Canagliflozin—Erythema—Dorzolamide—glaucoma	0.00124	0.00265	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.00123	0.00265	CcSEcCtD
Canagliflozin—Erythema—Travoprost—glaucoma	0.00123	0.00264	CcSEcCtD
Canagliflozin—Hypersensitivity—Levobunolol—glaucoma	0.00122	0.00262	CcSEcCtD
Canagliflozin—Infection—Apraclonidine—glaucoma	0.00122	0.00262	CcSEcCtD
Canagliflozin—Pruritus—Diclofenamide—glaucoma	0.00122	0.00262	CcSEcCtD
Canagliflozin—Breast disorder—Betaxolol—glaucoma	0.00122	0.00261	CcSEcCtD
Canagliflozin—Dry mouth—Bimatoprost—glaucoma	0.00122	0.00261	CcSEcCtD
Canagliflozin—Malnutrition—Brinzolamide—glaucoma	0.00121	0.0026	CcSEcCtD
Canagliflozin—Erythema—Brinzolamide—glaucoma	0.00121	0.0026	CcSEcCtD
Canagliflozin—Nervous system disorder—Apraclonidine—glaucoma	0.00121	0.00258	CcSEcCtD
Canagliflozin—Rash—Metipranolol—glaucoma	0.00119	0.00256	CcSEcCtD
Canagliflozin—Skin disorder—Apraclonidine—glaucoma	0.00119	0.00256	CcSEcCtD
Canagliflozin—Dermatitis—Metipranolol—glaucoma	0.00119	0.00256	CcSEcCtD
Canagliflozin—Asthenia—Levobunolol—glaucoma	0.00119	0.00255	CcSEcCtD
Canagliflozin—Infection—Bimatoprost—glaucoma	0.00118	0.00254	CcSEcCtD
Canagliflozin—Pruritus—Levobunolol—glaucoma	0.00117	0.00252	CcSEcCtD
Canagliflozin—Nervous system disorder—Bimatoprost—glaucoma	0.00117	0.00251	CcSEcCtD
Canagliflozin—Convulsion—Acetazolamide—glaucoma	0.00117	0.0025	CcSEcCtD
Canagliflozin—Dizziness—Carteolol—glaucoma	0.00116	0.00249	CcSEcCtD
Canagliflozin—Syncope—Brimonidine—glaucoma	0.00116	0.00249	CcSEcCtD
Canagliflozin—Urinary tract infection—Clonidine—glaucoma	0.00116	0.00249	CcSEcCtD
Canagliflozin—Skin disorder—Bimatoprost—glaucoma	0.00116	0.00248	CcSEcCtD
Canagliflozin—Dizziness—Diclofenamide—glaucoma	0.00114	0.00245	CcSEcCtD
Canagliflozin—Asthenia—Methazolamide—glaucoma	0.00114	0.00244	CcSEcCtD
Canagliflozin—Loss of consciousness—Brimonidine—glaucoma	0.00114	0.00244	CcSEcCtD
Canagliflozin—Angioedema—Dorzolamide—glaucoma	0.00113	0.00242	CcSEcCtD
Canagliflozin—Hypoglycaemia—Timolol—glaucoma	0.00113	0.00242	CcSEcCtD
Canagliflozin—Nausea—Metipranolol—glaucoma	0.00113	0.00241	CcSEcCtD
Canagliflozin—Dizziness—Carbachol—glaucoma	0.00111	0.00239	CcSEcCtD
Canagliflozin—Syncope—Dorzolamide—glaucoma	0.00111	0.00237	CcSEcCtD
Canagliflozin—Dizziness—Levobunolol—glaucoma	0.0011	0.00235	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.00109	0.00234	CcSEcCtD
Canagliflozin—Pruritus—Latanoprost—glaucoma	0.00109	0.00233	CcSEcCtD
Canagliflozin—Rash—Diclofenamide—glaucoma	0.00109	0.00233	CcSEcCtD
Canagliflozin—Loss of consciousness—Dorzolamide—glaucoma	0.00109	0.00233	CcSEcCtD
Canagliflozin—Shock—Acetazolamide—glaucoma	0.00108	0.00232	CcSEcCtD
Canagliflozin—Dry mouth—Brimonidine—glaucoma	0.00108	0.00231	CcSEcCtD
Canagliflozin—Rash—Carbachol—glaucoma	0.00106	0.00228	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00106	0.00228	CcSEcCtD
Canagliflozin—Dermatitis—Carbachol—glaucoma	0.00106	0.00227	CcSEcCtD
Canagliflozin—Fatigue—Apraclonidine—glaucoma	0.00106	0.00227	CcSEcCtD
Canagliflozin—Constipation—Apraclonidine—glaucoma	0.00105	0.00225	CcSEcCtD
Canagliflozin—Infection—Brimonidine—glaucoma	0.00105	0.00225	CcSEcCtD
Canagliflozin—Syncope—Pilocarpine—glaucoma	0.00105	0.00224	CcSEcCtD
Canagliflozin—Nausea—Carteolol—glaucoma	0.00104	0.00224	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.00104	0.00223	CcSEcCtD
Canagliflozin—Shock—Brimonidine—glaucoma	0.00104	0.00223	CcSEcCtD
Canagliflozin—Nervous system disorder—Brimonidine—glaucoma	0.00104	0.00222	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00103	0.00221	CcSEcCtD
Canagliflozin—Dry mouth—Dorzolamide—glaucoma	0.00103	0.0022	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00103	0.0022	CcSEcCtD
Canagliflozin—Loss of consciousness—Pilocarpine—glaucoma	0.00103	0.0022	CcSEcCtD
Canagliflozin—Skin disorder—Brimonidine—glaucoma	0.00103	0.0022	CcSEcCtD
Canagliflozin—Nausea—Diclofenamide—glaucoma	0.00102	0.0022	CcSEcCtD
Canagliflozin—Dry mouth—Travoprost—glaucoma	0.00102	0.0022	CcSEcCtD
Canagliflozin—Dizziness—Latanoprost—glaucoma	0.00102	0.00218	CcSEcCtD
Canagliflozin—Dry mouth—Brinzolamide—glaucoma	0.00101	0.00217	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Apraclonidine—glaucoma	0.00101	0.00216	CcSEcCtD
Canagliflozin—Rash—Methazolamide—glaucoma	0.001	0.00215	CcSEcCtD
Canagliflozin—Dermatitis—Methazolamide—glaucoma	0.001	0.00215	CcSEcCtD
Canagliflozin—Nausea—Carbachol—glaucoma	0.001	0.00214	CcSEcCtD
Canagliflozin—Infection—Travoprost—glaucoma	0.000997	0.00214	CcSEcCtD
Canagliflozin—Breast disorder—Timolol—glaucoma	0.000995	0.00213	CcSEcCtD
Canagliflozin—Shock—Dorzolamide—glaucoma	0.000992	0.00213	CcSEcCtD
Canagliflozin—Hypotension—Brimonidine—glaucoma	0.000986	0.00211	CcSEcCtD
Canagliflozin—Nausea—Levobunolol—glaucoma	0.000985	0.00211	CcSEcCtD
Canagliflozin—Infection—Brinzolamide—glaucoma	0.000985	0.00211	CcSEcCtD
Canagliflozin—Nervous system disorder—Travoprost—glaucoma	0.000984	0.00211	CcSEcCtD
Canagliflozin—Skin disorder—Travoprost—glaucoma	0.000975	0.00209	CcSEcCtD
Canagliflozin—Abdominal pain—Apraclonidine—glaucoma	0.000972	0.00208	CcSEcCtD
Canagliflozin—Nervous system disorder—Brinzolamide—glaucoma	0.000972	0.00208	CcSEcCtD
Canagliflozin—Angiopathy—Clonidine—glaucoma	0.000971	0.00208	CcSEcCtD
Canagliflozin—Rash—Latanoprost—glaucoma	0.00097	0.00208	CcSEcCtD
Canagliflozin—Dermatitis—Latanoprost—glaucoma	0.000969	0.00208	CcSEcCtD
Canagliflozin—Skin disorder—Brinzolamide—glaucoma	0.000963	0.00206	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000949	0.00204	CcSEcCtD
Canagliflozin—Fatigue—Acetazolamide—glaucoma	0.000948	0.00203	CcSEcCtD
Canagliflozin—Infection—Pilocarpine—glaucoma	0.000946	0.00203	CcSEcCtD
Canagliflozin—Nausea—Methazolamide—glaucoma	0.000944	0.00202	CcSEcCtD
Canagliflozin—Hypotension—Dorzolamide—glaucoma	0.000942	0.00202	CcSEcCtD
Canagliflozin—Hypotension—Travoprost—glaucoma	0.000938	0.00201	CcSEcCtD
Canagliflozin—Shock—Pilocarpine—glaucoma	0.000937	0.00201	CcSEcCtD
Canagliflozin—Erythema—Clonidine—glaucoma	0.000932	0.002	CcSEcCtD
Canagliflozin—Hypotension—Brinzolamide—glaucoma	0.000926	0.00199	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Brimonidine—glaucoma	0.000911	0.00195	CcSEcCtD
Canagliflozin—Fatigue—Brimonidine—glaucoma	0.00091	0.00195	CcSEcCtD
Canagliflozin—Hypersensitivity—Apraclonidine—glaucoma	0.000906	0.00194	CcSEcCtD
Canagliflozin—Hypotension—Pilocarpine—glaucoma	0.00089	0.00191	CcSEcCtD
Canagliflozin—Asthenia—Apraclonidine—glaucoma	0.000882	0.00189	CcSEcCtD
Canagliflozin—Urticaria—Acetazolamide—glaucoma	0.000874	0.00187	CcSEcCtD
Canagliflozin—Pruritus—Apraclonidine—glaucoma	0.00087	0.00186	CcSEcCtD
Canagliflozin—Fatigue—Dorzolamide—glaucoma	0.000869	0.00186	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Travoprost—glaucoma	0.000867	0.00186	CcSEcCtD
Canagliflozin—Fatigue—Travoprost—glaucoma	0.000865	0.00186	CcSEcCtD
Canagliflozin—Constipation—Travoprost—glaucoma	0.000858	0.00184	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000856	0.00183	CcSEcCtD
Canagliflozin—Asthenia—Bimatoprost—glaucoma	0.000855	0.00183	CcSEcCtD
Canagliflozin—Fatigue—Brinzolamide—glaucoma	0.000854	0.00183	CcSEcCtD
Canagliflozin—Angioedema—Clonidine—glaucoma	0.000852	0.00183	CcSEcCtD
Canagliflozin—Angiopathy—Betaxolol—glaucoma	0.000846	0.00181	CcSEcCtD
Canagliflozin—Pruritus—Bimatoprost—glaucoma	0.000843	0.00181	CcSEcCtD
Canagliflozin—Syncope—Clonidine—glaucoma	0.000836	0.00179	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dorzolamide—glaucoma	0.000824	0.00177	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000822	0.00176	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Travoprost—glaucoma	0.000821	0.00176	CcSEcCtD
Canagliflozin—Loss of consciousness—Clonidine—glaucoma	0.000819	0.00176	CcSEcCtD
Canagliflozin—Constipation—Pilocarpine—glaucoma	0.000815	0.00175	CcSEcCtD
Canagliflozin—Dizziness—Apraclonidine—glaucoma	0.000813	0.00174	CcSEcCtD
Canagliflozin—Erythema—Betaxolol—glaucoma	0.000811	0.00174	CcSEcCtD
Canagliflozin—Malnutrition—Betaxolol—glaucoma	0.000811	0.00174	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—SLC6A13—glaucoma	0.000803	0.00553	CbGpPWpGaD
Canagliflozin—Urticaria—Dorzolamide—glaucoma	0.000801	0.00172	CcSEcCtD
Canagliflozin—Abdominal pain—Dorzolamide—glaucoma	0.000797	0.00171	CcSEcCtD
Canagliflozin—Abdominal pain—Travoprost—glaucoma	0.000793	0.0017	CcSEcCtD
Canagliflozin—UGT2B4—Biological oxidations—GSTM1—glaucoma	0.000791	0.00545	CbGpPWpGaD
Canagliflozin—Asthenia—Acetazolamide—glaucoma	0.000789	0.00169	CcSEcCtD
Canagliflozin—Dizziness—Bimatoprost—glaucoma	0.000788	0.00169	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000788	0.00169	CcSEcCtD
Canagliflozin—Urticaria—Brinzolamide—glaucoma	0.000787	0.00169	CcSEcCtD
Canagliflozin—UGT1A9—Phase II conjugation—GSTT1—glaucoma	0.000785	0.00541	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—GSTM1—glaucoma	0.00078	0.00537	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Pilocarpine—glaucoma	0.000779	0.00167	CcSEcCtD
Canagliflozin—Hypersensitivity—Brimonidine—glaucoma	0.000778	0.00167	CcSEcCtD
Canagliflozin—Dry mouth—Clonidine—glaucoma	0.000776	0.00166	CcSEcCtD
Canagliflozin—ALB—Lipoprotein metabolism—ABCA1—glaucoma	0.000775	0.00534	CbGpPWpGaD
Canagliflozin—Dermatitis—Apraclonidine—glaucoma	0.000774	0.00166	CcSEcCtD
Canagliflozin—Asthenia—Brimonidine—glaucoma	0.000757	0.00162	CcSEcCtD
Canagliflozin—Infection—Clonidine—glaucoma	0.000756	0.00162	CcSEcCtD
Canagliflozin—Abdominal pain—Pilocarpine—glaucoma	0.000753	0.00161	CcSEcCtD
Canagliflozin—Rash—Bimatoprost—glaucoma	0.000752	0.00161	CcSEcCtD
Canagliflozin—Dermatitis—Bimatoprost—glaucoma	0.000751	0.00161	CcSEcCtD
Canagliflozin—Shock—Clonidine—glaucoma	0.000748	0.0016	CcSEcCtD
Canagliflozin—Pruritus—Brimonidine—glaucoma	0.000747	0.0016	CcSEcCtD
Canagliflozin—Nervous system disorder—Clonidine—glaucoma	0.000746	0.0016	CcSEcCtD
Canagliflozin—Hypersensitivity—Dorzolamide—glaucoma	0.000743	0.00159	CcSEcCtD
Canagliflozin—Hypersensitivity—Travoprost—glaucoma	0.000739	0.00159	CcSEcCtD
Canagliflozin—Skin disorder—Clonidine—glaucoma	0.000739	0.00158	CcSEcCtD
Canagliflozin—Nausea—Apraclonidine—glaucoma	0.00073	0.00157	CcSEcCtD
Canagliflozin—Hypersensitivity—Brinzolamide—glaucoma	0.00073	0.00157	CcSEcCtD
Canagliflozin—Syncope—Betaxolol—glaucoma	0.000728	0.00156	CcSEcCtD
Canagliflozin—Dizziness—Acetazolamide—glaucoma	0.000727	0.00156	CcSEcCtD
Canagliflozin—Asthenia—Dorzolamide—glaucoma	0.000723	0.00155	CcSEcCtD
Canagliflozin—Asthenia—Travoprost—glaucoma	0.00072	0.00154	CcSEcCtD
Canagliflozin—Pruritus—Dorzolamide—glaucoma	0.000713	0.00153	CcSEcCtD
Canagliflozin—Loss of consciousness—Betaxolol—glaucoma	0.000713	0.00153	CcSEcCtD
Canagliflozin—Asthenia—Brinzolamide—glaucoma	0.000711	0.00152	CcSEcCtD
Canagliflozin—Hypotension—Clonidine—glaucoma	0.000711	0.00152	CcSEcCtD
Canagliflozin—Pruritus—Travoprost—glaucoma	0.00071	0.00152	CcSEcCtD
Canagliflozin—Nausea—Bimatoprost—glaucoma	0.000708	0.00152	CcSEcCtD
Canagliflozin—Hypersensitivity—Pilocarpine—glaucoma	0.000702	0.0015	CcSEcCtD
Canagliflozin—Pruritus—Brinzolamide—glaucoma	0.000701	0.0015	CcSEcCtD
Canagliflozin—Dizziness—Brimonidine—glaucoma	0.000698	0.0015	CcSEcCtD
Canagliflozin—Angiopathy—Timolol—glaucoma	0.000691	0.00148	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000686	0.00147	CcSEcCtD
Canagliflozin—Asthenia—Pilocarpine—glaucoma	0.000683	0.00147	CcSEcCtD
Canagliflozin—Dry mouth—Betaxolol—glaucoma	0.000676	0.00145	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—TXN—glaucoma	0.000676	0.00465	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000675	0.00465	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000675	0.00465	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000675	0.00465	CbGpPWpGaD
Canagliflozin—Pruritus—Pilocarpine—glaucoma	0.000674	0.00144	CcSEcCtD
Canagliflozin—Dizziness—Dorzolamide—glaucoma	0.000667	0.00143	CcSEcCtD
Canagliflozin—Rash—Brimonidine—glaucoma	0.000666	0.00143	CcSEcCtD
Canagliflozin—Dermatitis—Brimonidine—glaucoma	0.000665	0.00143	CcSEcCtD
Canagliflozin—Dizziness—Travoprost—glaucoma	0.000664	0.00142	CcSEcCtD
Canagliflozin—Malnutrition—Timolol—glaucoma	0.000663	0.00142	CcSEcCtD
Canagliflozin—Erythema—Timolol—glaucoma	0.000663	0.00142	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—TXN—glaucoma	0.000659	0.00454	CbGpPWpGaD
Canagliflozin—Infection—Betaxolol—glaucoma	0.000658	0.00141	CcSEcCtD
Canagliflozin—SLC5A2—Disease—HEYL—glaucoma	0.000657	0.00453	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HEYL—glaucoma	0.000657	0.00453	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—FGFR1OP—glaucoma	0.000657	0.00453	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—FGFR1OP—glaucoma	0.000657	0.00453	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Clonidine—glaucoma	0.000657	0.00141	CcSEcCtD
Canagliflozin—Fatigue—Clonidine—glaucoma	0.000656	0.00141	CcSEcCtD
Canagliflozin—Dizziness—Brinzolamide—glaucoma	0.000655	0.0014	CcSEcCtD
Canagliflozin—Nausea—Acetazolamide—glaucoma	0.000653	0.0014	CcSEcCtD
Canagliflozin—Shock—Betaxolol—glaucoma	0.000652	0.0014	CcSEcCtD
Canagliflozin—Constipation—Clonidine—glaucoma	0.00065	0.00139	CcSEcCtD
Canagliflozin—Nervous system disorder—Betaxolol—glaucoma	0.000649	0.00139	CcSEcCtD
Canagliflozin—Skin disorder—Betaxolol—glaucoma	0.000643	0.00138	CcSEcCtD
Canagliflozin—Rash—Dorzolamide—glaucoma	0.000636	0.00136	CcSEcCtD
Canagliflozin—Dermatitis—Dorzolamide—glaucoma	0.000635	0.00136	CcSEcCtD
Canagliflozin—Rash—Travoprost—glaucoma	0.000633	0.00136	CcSEcCtD
Canagliflozin—Dermatitis—Travoprost—glaucoma	0.000632	0.00136	CcSEcCtD
Canagliflozin—Dizziness—Pilocarpine—glaucoma	0.00063	0.00135	CcSEcCtD
Canagliflozin—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.000629	0.00434	CbGpPWpGaD
Canagliflozin—Nausea—Brimonidine—glaucoma	0.000627	0.00134	CcSEcCtD
Canagliflozin—Rash—Brinzolamide—glaucoma	0.000625	0.00134	CcSEcCtD
Canagliflozin—Dermatitis—Brinzolamide—glaucoma	0.000624	0.00134	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Clonidine—glaucoma	0.000622	0.00133	CcSEcCtD
Canagliflozin—Hypotension—Betaxolol—glaucoma	0.000619	0.00133	CcSEcCtD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000614	0.00423	CbGpPWpGaD
Canagliflozin—Angioedema—Timolol—glaucoma	0.000606	0.0013	CcSEcCtD
Canagliflozin—Urticaria—Clonidine—glaucoma	0.000604	0.0013	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—SLC6A1—glaucoma	0.000602	0.00415	CbGpPWpGaD
Canagliflozin—Abdominal pain—Clonidine—glaucoma	0.000601	0.00129	CcSEcCtD
Canagliflozin—Rash—Pilocarpine—glaucoma	0.000601	0.00129	CcSEcCtD
Canagliflozin—Dermatitis—Pilocarpine—glaucoma	0.0006	0.00129	CcSEcCtD
Canagliflozin—Nausea—Dorzolamide—glaucoma	0.000599	0.00128	CcSEcCtD
Canagliflozin—Nausea—Travoprost—glaucoma	0.000596	0.00128	CcSEcCtD
Canagliflozin—Syncope—Timolol—glaucoma	0.000594	0.00127	CcSEcCtD
Canagliflozin—Nausea—Brinzolamide—glaucoma	0.000589	0.00126	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—SLC6A1—glaucoma	0.000587	0.00405	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Timolol—glaucoma	0.000583	0.00125	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betaxolol—glaucoma	0.000572	0.00123	CcSEcCtD
Canagliflozin—Fatigue—Betaxolol—glaucoma	0.000571	0.00122	CcSEcCtD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—PEX19—glaucoma	0.00057	0.00393	CbGpPWpGaD
Canagliflozin—Constipation—Betaxolol—glaucoma	0.000566	0.00121	CcSEcCtD
Canagliflozin—Nausea—Pilocarpine—glaucoma	0.000566	0.00121	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.00056	0.0012	CcSEcCtD
Canagliflozin—Hypersensitivity—Clonidine—glaucoma	0.00056	0.0012	CcSEcCtD
Canagliflozin—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000556	0.00383	CbGpPWpGaD
Canagliflozin—Dry mouth—Timolol—glaucoma	0.000552	0.00118	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—CA1—glaucoma	0.00055	0.00379	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CA1—glaucoma	0.00055	0.00379	CbGpPWpGaD
Canagliflozin—Asthenia—Clonidine—glaucoma	0.000546	0.00117	CcSEcCtD
Canagliflozin—Pruritus—Clonidine—glaucoma	0.000538	0.00115	CcSEcCtD
Canagliflozin—Infection—Timolol—glaucoma	0.000537	0.00115	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—CTSA—glaucoma	0.000533	0.00367	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CTSA—glaucoma	0.000533	0.00367	CbGpPWpGaD
Canagliflozin—Shock—Timolol—glaucoma	0.000532	0.00114	CcSEcCtD
Canagliflozin—Nervous system disorder—Timolol—glaucoma	0.000531	0.00114	CcSEcCtD
Canagliflozin—ALB—Selenium Micronutrient Network—TXN—glaucoma	0.00053	0.00365	CbGpPWpGaD
Canagliflozin—Urticaria—Betaxolol—glaucoma	0.000526	0.00113	CcSEcCtD
Canagliflozin—Skin disorder—Timolol—glaucoma	0.000525	0.00113	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—ABCA1—glaucoma	0.000523	0.00361	CbGpPWpGaD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—ABCA1—glaucoma	0.000515	0.00355	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—glaucoma	0.000512	0.00353	CbGpPWpGaD
Canagliflozin—ALB—Lipoprotein metabolism—APOE—glaucoma	0.00051	0.00351	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—ABCA1—glaucoma	0.000507	0.00349	CbGpPWpGaD
Canagliflozin—Hypotension—Timolol—glaucoma	0.000506	0.00108	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—CA2—glaucoma	0.000503	0.00347	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CA2—glaucoma	0.000503	0.00347	CbGpPWpGaD
Canagliflozin—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000503	0.00347	CbGpPWpGaD
Canagliflozin—Dizziness—Clonidine—glaucoma	0.000503	0.00108	CcSEcCtD
Canagliflozin—UGT1A9—Phase II conjugation—GSTM1—glaucoma	0.0005	0.00345	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB2—glaucoma	0.000491	0.00338	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Betaxolol—glaucoma	0.000488	0.00105	CcSEcCtD
Canagliflozin—Rash—Clonidine—glaucoma	0.00048	0.00103	CcSEcCtD
Canagliflozin—Dermatitis—Clonidine—glaucoma	0.000479	0.00103	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—TGFB2—glaucoma	0.000479	0.0033	CbGpPWpGaD
Canagliflozin—Asthenia—Betaxolol—glaucoma	0.000475	0.00102	CcSEcCtD
Canagliflozin—Pruritus—Betaxolol—glaucoma	0.000469	0.001	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Timolol—glaucoma	0.000467	0.001	CcSEcCtD
Canagliflozin—Fatigue—Timolol—glaucoma	0.000466	0.001	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—GSTT1—glaucoma	0.000459	0.00316	CbGpPWpGaD
Canagliflozin—Nausea—Clonidine—glaucoma	0.000452	0.000969	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—SOD1—glaucoma	0.000452	0.00311	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	0.000449	0.00309	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Timolol—glaucoma	0.000442	0.000948	CcSEcCtD
Canagliflozin—Dizziness—Betaxolol—glaucoma	0.000438	0.000939	CcSEcCtD
Canagliflozin—Urticaria—Timolol—glaucoma	0.00043	0.000921	CcSEcCtD
Canagliflozin—Abdominal pain—Timolol—glaucoma	0.000428	0.000917	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CA1—glaucoma	0.000425	0.00293	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—glaucoma	0.000422	0.00291	CbGpPWpGaD
Canagliflozin—Rash—Betaxolol—glaucoma	0.000418	0.000895	CcSEcCtD
Canagliflozin—Dermatitis—Betaxolol—glaucoma	0.000417	0.000894	CcSEcCtD
Canagliflozin—ALB—Platelet degranulation—TGFB2—glaucoma	0.000416	0.00286	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—ABCA1—glaucoma	0.000412	0.00284	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CTSA—glaucoma	0.000411	0.00283	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HDAC9—glaucoma	0.00041	0.00282	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HDAC9—glaucoma	0.00041	0.00282	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000407	0.0028	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Timolol—glaucoma	0.000399	0.000855	CcSEcCtD
Canagliflozin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—glaucoma	0.000397	0.00273	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—glaucoma	0.000396	0.00273	CbGpPWpGaD
Canagliflozin—Nausea—Betaxolol—glaucoma	0.000393	0.000843	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CA2—glaucoma	0.000389	0.00268	CbGpPWpGaD
Canagliflozin—Asthenia—Timolol—glaucoma	0.000388	0.000832	CcSEcCtD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000385	0.00265	CbGpPWpGaD
Canagliflozin—Pruritus—Timolol—glaucoma	0.000383	0.000821	CcSEcCtD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000378	0.00261	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD1—glaucoma	0.000368	0.00253	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—CYP1B1—glaucoma	0.000366	0.00252	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP1B1—glaucoma	0.000361	0.00249	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—MTHFR—glaucoma	0.000358	0.00247	CbGpPWpGaD
Canagliflozin—Dizziness—Timolol—glaucoma	0.000358	0.000767	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—TXN—glaucoma	0.000355	0.00244	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TXN—glaucoma	0.000355	0.00244	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—glaucoma	0.000353	0.00243	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000342	0.00236	CbGpPWpGaD
Canagliflozin—Rash—Timolol—glaucoma	0.000341	0.000731	CcSEcCtD
Canagliflozin—Dermatitis—Timolol—glaucoma	0.000341	0.000731	CcSEcCtD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—APOE—glaucoma	0.000339	0.00233	CbGpPWpGaD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—CAV1—glaucoma	0.000336	0.00231	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSTM1—glaucoma	0.000334	0.0023	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—APOE—glaucoma	0.000333	0.0023	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—ABCA1—glaucoma	0.000328	0.00226	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—GSTM1—glaucoma	0.000326	0.00224	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA5A—glaucoma	0.000322	0.00222	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NARFL—glaucoma	0.000322	0.00222	CbGpPWpGaD
Canagliflozin—Nausea—Timolol—glaucoma	0.000321	0.000689	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	0.00032	0.0022	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—SOD1—glaucoma	0.000315	0.00217	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PEX19—glaucoma	0.000306	0.00211	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—glaucoma	0.0003	0.00207	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000297	0.00205	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—GSTM1—glaucoma	0.000293	0.00202	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000292	0.00201	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD1—glaucoma	0.000292	0.00201	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—MTHFR—glaucoma	0.000291	0.00201	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSTM1—glaucoma	0.000289	0.00199	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTT1—glaucoma	0.000275	0.00189	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTT1—glaucoma	0.000275	0.00189	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TXN—glaucoma	0.000274	0.00189	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000271	0.00187	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000268	0.00185	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000257	0.00177	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL1A—glaucoma	0.000252	0.00173	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.00024	0.00165	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000237	0.00163	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—MTHFR—glaucoma	0.000231	0.00159	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FAS—glaucoma	0.000224	0.00154	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—C3—glaucoma	0.000221	0.00152	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN2B—glaucoma	0.00022	0.00152	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN2B—glaucoma	0.00022	0.00152	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—FN1—glaucoma	0.000219	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ABCA1—glaucoma	0.000219	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ABCA1—glaucoma	0.000219	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP1B1—glaucoma	0.000219	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP1B1—glaucoma	0.000219	0.00151	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTT1—glaucoma	0.000212	0.00146	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—FN1—glaucoma	0.000209	0.00144	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000207	0.00142	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000199	0.00137	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	0.000196	0.00135	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000195	0.00134	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000189	0.0013	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000188	0.0013	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MTHFR—glaucoma	0.000185	0.00127	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MTHFR—glaucoma	0.000185	0.00127	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000184	0.00127	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000181	0.00125	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000179	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTM1—glaucoma	0.000175	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTM1—glaucoma	0.000175	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APOE—glaucoma	0.000172	0.00119	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APOE—glaucoma	0.000172	0.00119	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CAV1—glaucoma	0.00017	0.00117	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CAV1—glaucoma	0.00017	0.00117	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1B1—glaucoma	0.000169	0.00117	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ABCA1—glaucoma	0.000169	0.00117	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA5A—glaucoma	0.000169	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NARFL—glaucoma	0.000169	0.00116	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—BAD—glaucoma	0.00016	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—BAD—glaucoma	0.00016	0.0011	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA1—glaucoma	0.000157	0.00108	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—MTHFR—glaucoma	0.000155	0.00107	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—MTHFR—glaucoma	0.000155	0.00107	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—glaucoma	0.000154	0.00106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CTSA—glaucoma	0.000152	0.00105	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA5A—glaucoma	0.000148	0.00102	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NARFL—glaucoma	0.000148	0.00102	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—glaucoma	0.000148	0.00102	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—APOE—glaucoma	0.000144	0.000993	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—APOE—glaucoma	0.000144	0.000993	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA2—glaucoma	0.000144	0.000991	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CAV1—glaucoma	0.000143	0.000983	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CAV1—glaucoma	0.000143	0.000983	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000141	0.000973	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000141	0.000968	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000141	0.000968	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.00014	0.000963	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000138	0.00095	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTM1—glaucoma	0.000135	0.000931	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.00013	0.000897	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTT1—glaucoma	0.00013	0.000894	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000129	0.000891	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS3—glaucoma	0.000129	0.000888	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS3—glaucoma	0.000129	0.000888	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	0.000128	0.000884	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—glaucoma	0.000126	0.000865	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—glaucoma	0.000125	0.000864	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000121	0.000832	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	0.00012	0.000824	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—MTHFR—glaucoma	0.00012	0.000823	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—glaucoma	0.000118	0.000812	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—glaucoma	0.000118	0.000812	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1B—glaucoma	0.000112	0.000769	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1B—glaucoma	0.000112	0.000769	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—APOE—glaucoma	0.000111	0.000766	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—glaucoma	0.000111	0.000765	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000111	0.000762	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—glaucoma	0.000111	0.000762	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CAV1—glaucoma	0.00011	0.000759	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NOS3—glaucoma	0.000108	0.000744	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NOS3—glaucoma	0.000108	0.000744	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1B1—glaucoma	0.000103	0.000713	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	0.000102	0.000703	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TXN—glaucoma	0.000101	0.000698	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000101	0.000695	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—glaucoma	9.97e-05	0.000687	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—glaucoma	9.87e-05	0.00068	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—glaucoma	9.87e-05	0.00068	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—FN1—glaucoma	9.73e-05	0.00067	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—glaucoma	9.52e-05	0.000656	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB2—glaucoma	9.51e-05	0.000655	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	9.46e-05	0.000652	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—glaucoma	9.25e-05	0.000637	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	9.16e-05	0.000631	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NARFL—glaucoma	9.1e-05	0.000627	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA5A—glaucoma	9.1e-05	0.000627	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	8.85e-05	0.000609	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NOS3—glaucoma	8.33e-05	0.000574	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—glaucoma	8.27e-05	0.00057	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA1—glaucoma	8.23e-05	0.000567	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	8.16e-05	0.000562	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CTSA—glaucoma	7.97e-05	0.000549	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTT1—glaucoma	7.86e-05	0.000541	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—glaucoma	7.62e-05	0.000525	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA2—glaucoma	7.53e-05	0.000519	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	7.36e-05	0.000507	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	7.36e-05	0.000507	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA1—glaucoma	7.21e-05	0.000497	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SOD1—glaucoma	7.21e-05	0.000496	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CTSA—glaucoma	6.99e-05	0.000481	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	6.96e-05	0.000479	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA2—glaucoma	6.6e-05	0.000454	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	6.59e-05	0.000454	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.34e-05	0.000436	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCA1—glaucoma	6.26e-05	0.000431	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1B1—glaucoma	6.26e-05	0.000431	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	5.57e-05	0.000384	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MMP1—glaucoma	5.49e-05	0.000379	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	5.48e-05	0.000378	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TXN—glaucoma	5.31e-05	0.000365	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CAV1—glaucoma	5.27e-05	0.000363	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FN1—glaucoma	5.01e-05	0.000345	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—glaucoma	5e-05	0.000345	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.84e-05	0.000333	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	4.8e-05	0.00033	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	4.7e-05	0.000324	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TXN—glaucoma	4.65e-05	0.00032	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA1—glaucoma	4.44e-05	0.000306	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—glaucoma	4.42e-05	0.000305	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CTSA—glaucoma	4.3e-05	0.000296	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	4.14e-05	0.000285	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—glaucoma	4.12e-05	0.000284	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—glaucoma	4.11e-05	0.000283	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAV1—glaucoma	4.08e-05	0.000281	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA2—glaucoma	4.06e-05	0.00028	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—glaucoma	3.98e-05	0.000274	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—glaucoma	3.6e-05	0.000248	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.32e-05	0.000228	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCA1—glaucoma	3.28e-05	0.000226	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1B1—glaucoma	3.28e-05	0.000226	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—glaucoma	3.08e-05	0.000212	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCA1—glaucoma	2.87e-05	0.000198	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1B1—glaucoma	2.87e-05	0.000198	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—glaucoma	2.87e-05	0.000198	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TXN—glaucoma	2.86e-05	0.000197	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—glaucoma	2.82e-05	0.000194	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—glaucoma	2.62e-05	0.00018	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—glaucoma	2.32e-05	0.00016	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—glaucoma	2.3e-05	0.000158	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—glaucoma	2.22e-05	0.000153	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—glaucoma	2.17e-05	0.000149	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—glaucoma	2.16e-05	0.000148	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAV1—glaucoma	2.14e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—glaucoma	2.03e-05	0.00014	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—glaucoma	1.89e-05	0.00013	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAV1—glaucoma	1.87e-05	0.000129	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1B1—glaucoma	1.77e-05	0.000122	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCA1—glaucoma	1.77e-05	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—glaucoma	1.62e-05	0.000111	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—glaucoma	1.48e-05	0.000102	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—glaucoma	1.42e-05	9.75e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—glaucoma	1.41e-05	9.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—glaucoma	1.29e-05	8.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—glaucoma	1.25e-05	8.61e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—glaucoma	1.16e-05	8.02e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAV1—glaucoma	1.15e-05	7.94e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—glaucoma	8.72e-06	6.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—glaucoma	7.97e-06	5.49e-05	CbGpPWpGaD
